Who We Are
PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.
Mission
PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.
Milestone
Research Collaboration
Seoul National University Hospital
Pre-series A Funding
Korea Investment Partners
KRW 1.5 B
Series A Funding
Korea Investment Partners, Hana Ventures, Timefolio
KRW 6 B
Bridge Funding
Korea Investment Partners, Hana Ventures, Timefolio
KRW 4.5 B
Mitochondria GMP Facility
Jung-gu, Seoul
PN-101 MFDS IND Approval
World-first allogeneic mitochondria as therapeutic agent
Research Collaboration
MOU with Soonchunhyang University Medical Center and SIMS
Press Highlights
파이안바이오 "미토콘드리아 치료제, 해외 제약사 2곳과 공동연구"
Source: https://www.hankyung.com/it/article/202207122116i
Read more >>
미토콘드리아 치료제 세계 첫 임상… 면역세포 치료-항암제까지
Source: https://www.donga.com/news/It/article/all/20220423/113035474/1?ref=main
Read more >>
파이안바이오 “미토콘드리아 유럽 임상 위한 CMO 계약 논의”
Source: https://www.hankyung.com/it/article/202112071993i
Read more >>